Literature DB >> 29037921

TLR expression profile of human alveolar bone proper-derived stem/progenitor cells and osteoblasts.

Karim M Fawzy El-Sayed1, Josephine Boeckler2, Christof E Dörfer2.   

Abstract

Alveolar bone proper-derived mesenchymal stem/progenitor cells (AB-MSCs) and alveolar osteoblasts (OBs) are pivotal cells with positive attributes in regenerative medicine. During regenerative approaches, AB-MSCs may interact with their surrounding environment via their expressed toll-like-receptors (TLRs). This study aimed to depict for the first time the TLRs expression profile of AB-MSCs and OBs. Cells were isolated from human alveolar bone proper, and STRO-1-immunomagnetically sorted to segregate AB-MSCs and OBs. Cell populations were separately seeded out to obtain single colony forming units (CFUs), and were characterized for CD14, CD34, CD45, CD73, CD90, CD105, and CD146 expression as well as for their multilineage differentiation potential. Following incubation of AB-MSCs and OBs in basic medium, their TLRs expression profiles were characterized at mRNA and protein levels. In contrast to OBs, AB-MSCs showed all predefined mesenchymal stem/progenitor cell characteristics. At a protein level, AB-MSCs showed a distinctive expression profile of TLRs 1, 2, 3, 4, 5, 6, 7, 8, and 10 in different quantities, without TLR9 expression. According to their median expression values, TLR2 was the highest expressed, followed by TLRs 4, 5, 7, 1, 10, 8, 3, and finally 6. In contrast, OBs did not express TLR3 and TLR9. According to their median expression values they further showed a different sequence of TLRs expression, with TLR2 highest expressed, followed by TLRs 10, 4, 7, 5, 1, 8, and 6. This study describes for the first time the characteristic TLRs expression profile of AB-MSCs as well as OBs, which could impact their specific sensitivity to pathogenic as well as body tissue compounds, and their therapeutic potential in-vivo.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Alveolar bone; FACS; Polymerase chain reaction; Stem cells; TLR

Mesh:

Substances:

Year:  2017        PMID: 29037921     DOI: 10.1016/j.jcms.2017.09.007

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

Review 1.  Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.

Authors:  Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Sara El Moshy; Israa Ahmed Radwan; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-08-11       Impact factor: 5.443

2.  Thymoquinone-Mediated Modulation of Toll-like Receptors and Pluripotency Factors in Gingival Mesenchymal Stem/Progenitor Cells.

Authors:  Mohamed Mekhemar; Johannes Tölle; Yasmine Hassan; Christof Dörfer; Karim Fawzy El-Sayed
Journal:  Cells       Date:  2022-04-25       Impact factor: 7.666

3.  Identification of a Novel Osteogenetic Oligodeoxynucleotide (osteoDN) That Promotes Osteoblast Differentiation in a TLR9-Independent Manner.

Authors:  Yuma Nihashi; Mana Miyoshi; Koji Umezawa; Takeshi Shimosato; Tomohide Takaya
Journal:  Nanomaterials (Basel)       Date:  2022-05-14       Impact factor: 5.719

4.  Exposure of zebra mussels to extracorporeal shock waves demonstrates formation of new mineralized tissue inside and outside the focus zone.

Authors:  Katharina Sternecker; Juergen Geist; Sebastian Beggel; Kristin Dietz-Laursonn; Matias de la Fuente; Hans-Georg Frank; John P Furia; Stefan Milz; Christoph Schmitz
Journal:  Biol Open       Date:  2018-07-02       Impact factor: 2.422

Review 5.  Dental Stem Cell-Derived Secretome/Conditioned Medium: The Future for Regenerative Therapeutic Applications.

Authors:  Sara El Moshy; Israa Ahmed Radwan; Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Khadiga M Sadek; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-01-31       Impact factor: 5.443

Review 6.  Toll-Like Receptors and Dental Mesenchymal Stromal Cells.

Authors:  Oleh Andrukhov
Journal:  Front Oral Health       Date:  2021-04-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.